Francesco Vitiello

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi-Center Real-World Study.

Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi-Center Real-World Study.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: August 13, 2025

Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting.

Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting.

Journal: Targeted oncology

Published: June 03, 2025

Impact of antibiotic therapy in patients with cholangiocarcinoma treated with chemoimmunotherapy.

Impact of antibiotic therapy in patients with cholangiocarcinoma treated with chemoimmunotherapy.

Journal: Oncology

Published: March 25, 2025

HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions.

HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions.

Journal: Targeted oncology

Published: February 05, 2025

Intermediate hepatocellular carcinoma: new horizons and prospects for our patients.

Intermediate hepatocellular carcinoma: new horizons and prospects for our patients.

Journal: Expert review of gastroenterology & hepatology

Published: November 01, 2024

Anti-Human Epidermal Growth Factor Receptor-2 Therapies in Biliary Tract Cancers: A Meta-Analysis on Disease Location, Human Epidermal Growth Factor Receptor-2 Status, and Survival Outcomes.

Anti-Human Epidermal Growth Factor Receptor-2 Therapies in Biliary Tract Cancers: A Meta-Analysis on Disease Location, Human Epidermal Growth Factor Receptor-2 Status, and Survival Outcomes.

Journal: Oncology

Published: October 22, 2024

Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study.

Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study.

Journal: International journal of cancer

Published: October 19, 2024

Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population.

Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population.

Journal: Seminars in oncology

Published: August 13, 2024

Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution.

Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution.

Journal: Oncology

Published: August 08, 2024

Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents.

Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents.

Journal: Expert opinion on investigational drugs

Published: July 23, 2024

Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art.

Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art.

Journal: Expert review of gastroenterology & hepatology

Published: April 08, 2024

Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab.

Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab.

Journal: Targeted oncology

Published: April 03, 2024

Showing 1-12 of 21

Last Updated: 09/26/2026